Measurable Residual Disease for AML by Flow Cytometry (Pilot -Not Accredited)

The measurement of Measurable Residual Disease (MRD) populations is often performed following treatment for leukaemic disorders. The levels of MRD are used as a predictive factor for relapse and as an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.

The Measurable Residual Disease in AML programme will issue up to four send outs per financial year.  Each send out will include a reference sample and two follow up samples of a known AML case post treatment at different time points.

Participants will be asked to quantify the level of residual disease in the follow up samples. If you wish to be involved in the study please contact admin@ukneqasli.co.uk. 

Trials for this programme are live/open for a minimum of 3 weeks.

Please Note: Trials issued/closing in August or December are extended by 1 week.

An automated email is sent 2 days prior to the trial closing, to any participant that has not returned results, warning them of the trial closure date. 

 ***NEW IN 2022-2023*** The Minimal Residual Disease Programmes have been renamed in line with current naming conventions and will now be called Measurable Residual Disease Programmes. All other aspects of the programme operation will remain unchanged.

No activities in relation to this EQA programme are subcontracted.

To register for this programme, please click here.